Indivior’s 2025 outlook missed estimates, citing Suboxone sales erosion. The company plans $100 million in cost cuts, with $50M reinvested in Sublocade.
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat
